US › Healthcare

Acumen Pharmaceuticals Inc (ABOS)

US · Healthcare · Biotechnology

$2.24+2.75%
Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue
$0
Net profit
$-20.7M
Profit YoY
+28.0%
EPS
$-0.33
EPS estimate
$-0.46

EPS came in at -0.33 against a street estimate of -0.46 — a beat of 28.3%.

Key statistics

Market cap
$155.3M
Forward P/E
0.0
P/B
1.78
Book value
$1.21
EPS (TTM)
$-1.86
52-week high
$3.60
52-week low
$1.19
50-day MA
$2.38
200-day MA
$2.35
Beta
0.34

Analyst view

Analysts rate Acumen Pharmaceuticals Inc a strong buy (5 buy, 0 hold, 0 sell out of 5) with an average price target of $7.40.

Shareholding

Insiders
6.80%
Institutions
64.69%

Largest institutional holders

FundStake
RA Capital Management, LLC29.06%
Sands Capital Ventures, LLC5.15%
Alyeska Investment Group, L.P.3.40%
Franklin Resources Inc3.19%
ADAR1 Capital Management LLC2.99%
Knollwood Investment Advisory LLC2.25%
Vanguard Capital Management, LLC2.09%
FMR Inc1.60%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Acumen Pharmaceuticals Inc — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncNovo Nordisk A/SAmgen IncAbbott LaboratoriesGilead Sciences Inc

Data updated 2026-08-05.